Profund Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $390K | Sell |
77,026
-46,098
| -37% | -$233K | 0.01% | 554 |
|
|
2025
Q1 | $651K | Buy |
123,124
+8,238
| +7% | +$43.6K | 0.03% | 402 |
|
|
2024
Q4 | $777K | Sell |
114,886
-17,925
| -13% | -$121K | 0.03% | 351 |
|
|
2024
Q3 | $875K | Buy |
132,811
+58,040
| +78% | +$382K | 0.03% | 357 |
|
|
2024
Q2 | $561K | Sell |
74,771
-52,385
| -41% | -$393K | 0.02% | 467 |
|
|
2024
Q1 | $1.27M | Sell |
127,156
-35,469
| -22% | -$354K | 0.05% | 298 |
|
|
2023
Q4 | $1.6M | Sell |
162,625
-21,610
| -12% | -$213K | 0.07% | 225 |
|
|
2023
Q3 | $1.41M | Buy |
184,235
+124,621
| +209% | +$953K | 0.08% | 206 |
|
|
2023
Q2 | $445K | Sell |
59,614
-11,610
| -16% | -$86.7K | 0.02% | 548 |
|
|
2023
Q1 | $475K | Buy |
+71,224
| New | +$475K | 0.03% | 516 |
|